T1	Participants 101 150	patients with advanced or recurrent breast cancer
T2	Participants 950 978	221 patients were assessable
T3	Participants 1775 1818	patients who had not received prior therapy
T4	Participants 1361 1475	patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor
